Holen Sie sich die Stockscreener-App
25.55
2.89%
-0.76
Handel nachbörslich:
25.55
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CAPR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$26.31
Offen:
$25.86
24-Stunden-Volumen:
854.41K
Relative Volume:
0.32
Marktkapitalisierung:
$1.39B
Einnahmen:
$27.10M
Nettoeinkommen (Verlust:
$-24.31M
KGV:
-30.78
EPS:
-0.83
Netto-Cashflow:
$-33.33M
1W Leistung:
-11.47%
1M Leistung:
-10.54%
6M Leistung:
+151.23%
1J Leistung:
+84.34%
1-Tages-Spanne:
$25.07
$26.22
1-Wochen-Bereich:
$24.34
$29.36
52-Wochen-Spanne:
$4.30
$40.37
Capricor Therapeutics Inc Stock (CAPR) Company Profile
Firmenname
Capricor Therapeutics Inc
Sektor
Branche
Telefon
(310) 358-3200
Adresse
10865 ROAD TO THE CURE, SAN DIEGO, CA
Vergleichen Sie CAPR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CAPR
Capricor Therapeutics Inc
|
25.55 | 1.43B | 27.10M | -24.31M | -33.33M | -0.83 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Capricor Therapeutics Inc Stock (CAPR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-30 | Eingeleitet | Alliance Global Partners | Buy |
| 2025-06-26 | Eingeleitet | B. Riley Securities | Buy |
| 2025-05-20 | Eingeleitet | Roth Capital | Buy |
| 2024-10-21 | Eingeleitet | Piper Sandler | Overweight |
| 2024-05-17 | Eingeleitet | Oppenheimer | Outperform |
| 2024-01-05 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2022-10-26 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-26 | Herabstufung | Maxim Group | Buy → Hold |
| 2018-01-26 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2017-02-13 | Fortgesetzt | Rodman & Renshaw | Buy |
| 2016-07-06 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-06-15 | Eingeleitet | ROTH Capital | Buy |
Alle ansehen
Capricor Therapeutics Inc Aktie (CAPR) Neueste Nachrichten
How interest rate cuts could boost Capricor Therapeutics Inc. stockMarket Trend Summary & Real-Time Volume Spike Alerts - ulpravda.ru
Can Capricor Therapeutics Inc. stock weather global recession2025 Geopolitical Influence & Technical Pattern Recognition Alerts - ulpravda.ru
Capricor Therapeutics, Inc.Common Stock (NQ: CAPR - FinancialContent
(CAPR) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Capricor Therapeutics (NASDAQ:CAPR) Shares Down 7.8%What's Next? - MarketBeat
‘Pharma Bro’ Martin Shkreli Calls His Capricor Therapeutics Short A 'Bad Call' After DMD Trial Delivers Surprise Win - MSN
Capricor Therapeutics, Inc. (NASDAQ:CAPR) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Capricor Therapeutics (NASDAQ:CAPR) Upgraded at Wall Street Zen - MarketBeat
‘Pharma Bro’ Martin Shkreli Goes Short On Capricor Therapeutics – Stock Tumbles 17% - MSN
Capricor Therapeutics (NASDAQ:CAPR) Stock Price Down 4.5%Here's What Happened - MarketBeat
Best Biotech Stocks To ConsiderDecember 7th - MarketBeat
HBK Sorce Advisory LLC Buys 42,951 Shares of Capricor Therapeutics, Inc. $CAPR - MarketBeat
Analyst Downgrade: How interest rate cuts could boost Capricor Therapeutics Inc stockWeekly Stock Analysis & Daily Profit Focused Stock Screening - moha.gov.vn
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Capricor Therapeutics, Inc. (CAPR) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
(CAPR) Volatility Zones as Tactical Triggers - Stock Traders Daily
Trend Review: Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Buyback Activity & Safe Investment Capital Preservation Plans - moha.gov.vn
HBK Sorce Advisory LLC Raises Stake in Capricor Therapeutics, Inc. $CAPR - MarketBeat
Short Interest in Capricor Therapeutics, Inc. (NASDAQ:CAPR) Decreases By 69.4% - MarketBeat
Gene therapy genie back in the bottle? - BioWorld MedTech
Capricor Therapeutics prices $150M stock offering - MSN
Capricor Therapeutics (CAPR) price target increased by 32.98% to 51.82 - MSN
Top Medical Stocks To ResearchDecember 3rd - MarketBeat
Assessing Capricor Therapeutics (CAPR) Valuation After Positive HOPE-3 Data and Nippon Shinyaku Commercialization Deal - Sahm
Capricor Therapeutics launches proposed public offering of common stock - MSN
Earnings Risk: Is ARK Autonomous Technology & Robotics stock cheap by valuation metricsMarket Trend Summary & Free Weekly Chart Analysis and Trade Guides - moha.gov.vn
Why Capricor Therapeutics Inc. stock attracts high net worth investors2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
How Capricor Therapeutics Inc. (4LN2) stock trades pre earningsQuarterly Earnings Summary & Fast Entry Momentum Trade Alerts - ulpravda.ru
Does Capricor Therapeutics Inc. stock trade at a discount to peers2025 Analyst Calls & Advanced Technical Signal Analysis - ulpravda.ru
Capricor Therapeutics (NASDAQ:CAPR) Shares Up 9.8%What's Next? - MarketBeat
Capricor Therapeutics (STU:4LN2) EV-to-OCF : -21.03 (As of Dec. 19, 2025) - GuruFocus
Capricor Therapeutics (STU:4LN2) EV-to-FCF : -18.80 (As of Dec. 19, 2025) - GuruFocus
Can Capricor Therapeutics Inc. stock reach $100 price target2025 Pullback Review & Weekly Sector Rotation Insights - ulpravda.ru
Why Capricor Therapeutics Inc. (4LN2) stock is a strong analyst pick2025 Bull vs Bear & Low Drawdown Investment Ideas - DonanımHaber
CAPR stock price: Why is Capricor Therapeutics stock surging over 293% today? - MSN
Can Capricor Therapeutics Inc. (4LN2) stock double in coming years2025 Earnings Surprises & Detailed Earnings Play Alerts - Улправда
How Capricor Therapeutics Inc. stock reacts to global recession fears2025 Risk Factors & Weekly Stock Breakout Alerts - Улправда
How Capricor Therapeutics Inc. (4LN2) stock benefits from digital adoptionRecession Risk & Target Return Focused Stock Picks - Улправда
Capricor Therapeutics, Inc. (CAPR): A Bear Case Theory - Insider Monkey
Is Capricor Therapeutics Inc. stock attractive for long term wealth building2025 Price Targets & Smart Investment Allocation Tips - Улправда
Transcript : Capricor Therapeutics, Inc.Special Call - marketscreener.com
Piper Sandler reiterates Capricor stock rating, names it 2026 top pick - Investing.com UK
PPMD to host webinar on Capricor’s DMD therapy trial results By Investing.com - Investing.com Canada
Capricor Therapeutics Announces Community Webinar on Positive HOPE-3 Trial Results for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative
Capricor Therapeutics and Parent Project Muscular Dystrophy to Host Webinar Highlighting Positive Phase 3 HOPE-3 Topline Results in Duchenne Muscular Dystrophy - The Manila Times
Capricor Therapeutics and Parent Project Muscular Dystrophy - GlobeNewswire
CAPR: B. Riley Securities Raises Target Price to $50, Maintains Buy Rating | CAPR Stock News - GuruFocus
B. Riley Adjusts Price Target on Capricor Therapeutics to $50 From $21, Maintains Buy Rating - marketscreener.com
Understanding the Setup: (CAPR) and Scalable Risk - news.stocktradersdaily.com
Capricor Therapeutics (CAPR): Reassessing Valuation After Positive Phase 3 HOPE-3 Results for Deramiocel - Sahm
How Investors May Respond To Capricor Therapeutics (CAPR) Phase 3 HOPE-3 Success And $150 Million Equity Raise - Sahm
Sidley Represents Capricor Therapeutics in US$172.5 Million Common Stock Offering - Sidley Austin
Finanzdaten der Capricor Therapeutics Inc-Aktie (CAPR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
4.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):